Breast cancer research and study information will be prevalent over the next couple of months ,as we move towards national Breast Cancer Awareness Month. For many women breast cancer is a reality that spans much further than 1 to 2 months a year. According to an online published article early study results show promise in the creation of a breast cancer vaccine. According to the article the vaccine that is in the process of development is geared towards preventing the recurrence of breast cancer in women who have a form of tumor that is known as Her2- positive, according to researcher Dr. Diane Hale, a research resident in general surgery at Brooke Army Medical Center at Fort Sam Houston, in San Antonio. The vaccine is called the “HER2-based peptide vaccine AE37,” and is designed to take advantage of the power of the patient’s immune system based on its reaction to a cancer linked peptide or protein. “The theory is that once you form that [immune] response to the specific peptide, if the body has a recurrence, it will recognize that cancer as a bad thing, a foreign thing,” Hale explained in an association news release. At the time of the online publishing of the article the vaccine was in the phase 2 stage and was still in need of phase 3 before it could be approved. Scientists were cautious and stressed that the study results are early and even if phase 2 and phase 3 yield positive results the vaccine could still take at least five years before it would be available.
Breast cancer research and study information will be prevalent over the next couple of months ,as we move towards national Breast Cancer Awareness Month. For many women breast cancer is a reality that spans much further than 1 to 2 months a year. According to an online published article early study results show promise in the creation of a breast cancer vaccine. According to the article the vaccine that is in the process of development is geared towards preventing the recurrence of breast cancer in women who have a form of tumor that is known as Her2- positive, according to researcher Dr. Diane Hale, a research resident in general surgery at Brooke Army Medical Center at Fort Sam Houston, in San Antonio. The vaccine is called the “HER2-based peptide vaccine AE37,” and is designed to take advantage of the power of the patient’s immune system based on its reaction to a cancer linked peptide or protein. “The theory is that once you form that [immune] response to the specific peptide, if the body has a recurrence, it will recognize that cancer as a bad thing, a foreign thing,” Hale explained in an association news release. At the time of the online publishing of the article the vaccine was in the phase 2 stage and was still in need of phase 3 before it could be approved. Scientists were cautious and stressed that the study results are early and even if phase 2 and phase 3 yield positive results the vaccine could still take at least five years before it would be available.